Explore more publications!
Health Update Bahamas
Got News to Share?

Health Update Bahamas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Update Bahamas.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 11, 2025

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
December 11, 2025

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain

Indeterminate GlobeNewswire
Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
December 11, 2025

Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio

Indeterminate GlobeNewswire
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
December 11, 2025

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

Indeterminate GlobeNewswire
Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229
December 11, 2025

Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229

Indeterminate GlobeNewswire
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
December 11, 2025

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Indeterminate GlobeNewswire
ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases
December 11, 2025

ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases

Indeterminate GlobeNewswire
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
December 11, 2025

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Indeterminate GlobeNewswire
ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors
December 11, 2025

ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors

Indeterminate GlobeNewswire
Hope for PDCD Foundation Delivers Petition to FDA Urging Approval of the First Targeted PDCD Treatment
December 11, 2025

Hope for PDCD Foundation Delivers Petition to FDA Urging Approval of the First Targeted PDCD Treatment

Indeterminate GlobeNewswire
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
December 11, 2025

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

Indeterminate GlobeNewswire
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
December 11, 2025

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

Indeterminate GlobeNewswire
Ophirex Announces Business Update: Advances Toward Food and Drug Administration (FDA) Approval for Varespladib as Novel Oral Snakebite Treatment
December 11, 2025

Ophirex Announces Business Update: Advances Toward Food and Drug Administration (FDA) Approval for Varespladib as Novel Oral Snakebite Treatment

Indeterminate GlobeNewswire
PatchMD Launches New Dopamine Support Patch for Natural Mood and Focus Support
December 11, 2025

PatchMD Launches New Dopamine Support Patch for Natural Mood and Focus Support

Indeterminate GlobeNewswire
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
December 11, 2025

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas

Indeterminate GlobeNewswire
Plus Therapeutics Expands CNSide Assay Platform to State of California
December 11, 2025

Plus Therapeutics Expands CNSide Assay Platform to State of California

Indeterminate GlobeNewswire
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
December 11, 2025

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

Indeterminate GlobeNewswire
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
December 11, 2025

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

Indeterminate GlobeNewswire
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
December 11, 2025

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Indeterminate GlobeNewswire
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
December 11, 2025

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Indeterminate GlobeNewswire
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer
December 11, 2025

Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions